46 results on '"DeJong, Colette"'
Search Results
2. Heart failure with preserved ejection fraction
3. Stakeholder Perspectives on a Heart Failure With Reduced Ejection Fraction Polypill: A Multi-Center Mixed Methods Study
4. Abstract 4142190: Patient-Reported Health Status Among Patients with Heart Failure with Improved Ejection Fraction
5. Abstract 15872: Development and External Validation of a De Novo Simulation Model to Inform Implementation Strategies for Guideline-Directed Medical Therapy of Heart Failure With Reduced Ejection Fraction
6. Variation in Quality of Urgent Health Care Provided During Commercial Virtual Visits
7. Disclosure of Article Funding and Conflicts of Interest in High-Impact Clinical Journals
8. Association Between Industry Marketing Payments and Prescriptions for PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors in the United States
9. The Inflation Reduction Act and Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Disease
10. IMPACT OF THE $35 INSULIN PROGRAM ON OUT-OF-POCKET COSTS UNDER MEDICARE PART D
11. PROJECTED IMPACT OF THE INFLATION REDUCTION ACT ON OUT-OF-POCKET DRUG COSTS FOR MEDICARE PART D BENEFICIARIES WITH CARDIOVASCULAR DISEASE
12. THE INFLATION REDUCTION ACT WILL CHANGE WHO PAYS FOR CARDIOVASCULAR DRUGS UNDER MEDICARE PART D
13. Spending on Insulin by U.S. Payers and Patients From 2008 to 2017
14. Patients’ Compliance With Quarantine Requirements for Exposure or Potential Symptoms of COVID-19
15. A Pilot Program to Teach Pharmacy Students Practical Skills to Navigate Drug Insurance Benefits
16. Incorporating a New Technology While Doing No Harm, Virtually
17. Deferral of Care for Serious Non–COVID-19 Conditions
18. Websites That Offer Care Over the Internet: Is There an Access Quality Tradeoff?
19. Trends in the Use of Angiotensin-Converting Enzyme Inhibitor and Angiotensin-II Receptor Blocker Among United States Adults From 1999 to 2018
20. Tenofovir-based PrEP for COVID-19: an untapped opportunity?
21. Out-of-Pocket Costs for Novel Guideline-Directed Diabetes Therapies Under Medicare Part D
22. Inclusion Across the Lifespan in Cardiovascular Trials—A Long Road Ahead
23. Multivessel or Culprit Vessel–Only Percutaneous Coronary Intervention for Patients With Acute Myocardial Infarction and Cardiogenic Shock
24. The Risks of Prescribing Hydroxychloroquine for Treatment of COVID-19—First, Do No Harm
25. An Ethical Framework for Allocating Scarce Inpatient Medications for COVID-19 in the US
26. Continuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Face of Kidney Disease Progression—Safe and Possibly Life Saving
27. Addressing Mistreatment in Medical Education
28. Patients' Compliance With Quarantine Requirements for Exposure or Potential Symptoms of COVID-19.
29. Shining a Light on Industry Payments to Health Care Professionals Who Are Not Physicians
30. Assessment of National Coverage and Out-of-Pocket Costs for Sacubitril/Valsartan Under Medicare Part D
31. Supplemental Security Income and the Health of Low-Income Adults
32. Electrocardiographic Harbingers of Ventricular Tachycardia Arrest—A Moment of Pause
33. Validation of Prediction Models for Critical Care Outcomes Using Natural Language Processing of Electronic Health Record Data
34. Continuing Problems With Financial Conflicts of Interest and Clinical Practice Guidelines
35. DIRECT-TO-PHYSICIAN MARKETING AND ADOPTION OF GUIDELINE-DIRECTED MEDICAL THERAPY IN MEDICARE PART D.
36. PATIENT AND PROVIDER PERSPECTIVES ON A POLYPILL FOR HEART FAILURE WITH REDUCED EJECTION FRACTION.
37. Nationwide Coverage and Cost-Sharing for PCSK9 Inhibitors Among Medicare Part D Plans
38. Reconsidering Physician–Pharmaceutical Industry Relationships
39. Medicare Part D Plans’ Coverage and Cost-Sharing for Acute Rescue and Preventive Inhalers for Chronic Obstructive Pulmonary Disease
40. Important Distinctions Concerning Pharmaceutical Company–Sponsored Meals and Prescribing Patterns—Reply
41. Pharmaceutical Industry–Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries
42. Medicare Part D Plans' Coverage and Cost-Sharing for Acute Rescue and Preventive Inhalers for Chronic Obstructive Pulmonary Disease.
43. Short Communication: New HIV Infections at Southern New England Academic Institutions: Implications for Prevention
44. Important Distinctions Concerning Pharmaceutical Company-Sponsored Meals and Prescribing Patterns.
45. Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries.
46. Patients' Compliance With Quarantine Requirements for Exposure or Potential Symptoms of COVID-19.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.